Skip to main content
. 2020 Apr 2;4:PO.19.00281. doi: 10.1200/PO.19.00281

FIG 2.

FIG 2.

Overall survival according to the presence of ALK resistance mutations or other mutations in the liquid biopsy in ALK positive population. (A) PD while receiving TKI therapy, by ALK status. (B) PD while receiving TKI therapy, by ALK type. PD, disease progression; TKI, tyrosine kinase inhibitor.